arrow
S

Simone Ferrero

department of molecular biotechnologies and health sciences
H指数:35
被引数:6,903

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study

边缘区淋巴瘤首次复发后的生存情况:国际观察性NF10研究的前瞻性数据

2026-09-060
OAAI
RENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed/refractory follicular lymphoma

RENOIR三期研究:利妥昔单抗-来那度胺对比利妥昔单抗作为复发/难治性滤泡性淋巴瘤的维持治疗

2026-09-010
PRE
Clinical impact of immunoglobulin heavy chain repertoire in mantle cell lymphoma: A study from the Fondazione Italiana Linfomi (FIL) Phase III MCL0208 trial

免疫球蛋白重链库对套细胞淋巴瘤的临床影响: 来自Fondazione Italiana Linfomi (FIL) III期MCL0208试验的研究

2026-01-200
OAAI
Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy

吡罗布鲁替尼在复发或难治性套细胞淋巴瘤中的应用:来自意大利同情用药项目的结果

2026-01-010
PRE
Evaluation of the Role of AID-Induced Mutagenesis in Resistance to B-Cell Receptor Pathway Inhibitors in Chronic Lymphocytic Leukemia

评估AID诱导突变在慢性淋巴细胞白血病中对B细胞受体通路抑制剂耐药性的作用

2025-12-100
OA
The role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: Results from the ELDERLY MANTLE-FIRST study

老年套细胞淋巴瘤患者中,首次进展时间和体能状态的作用:ELDERLY MANTLE-FIRST研究的结果

2025-12-010
OAAI
Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R)

vemurafenib联合利妥昔单抗治疗复发或难治性毛细胞白血病的真实世界疗效与安全性:一项多中心意大利回顾性研究(HCL-PG03R)

2025-11-140
OAAI
The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial

基因突变与拷贝数变异的整合优化了套细胞淋巴瘤的预后:意大利淋巴瘤基金会MCL0208临床试验的长期结果

Leukemia
IF13.4
2025-11-070
OAAI
Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial

非侵入性基因分型及早期疾病动态变化表明,在TRIANGLE试验中接受治疗的套细胞淋巴瘤患者中,伊布替尼联合免疫化疗的疗效。

Leukemia
IF13.4
2025-11-030
OAAI
The role of the Androgen Receptor (AR) in endometrial cancer aggressiveness: Correlation with other prognostic markers and therapeutic implications. A retrospective observational study

雄激素受体(AR)在子宫内膜癌侵袭性中的作用:与其他预后标志物的相关性及治疗意义。一项回顾性观察性研究

2025-05-010
OAAI
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s Macroglobulinemia

第十二届瓦尔登斯特罗姆巨球蛋白血症患者 Bing-Neel 综合症管理国际研讨会共识小组 2 的报告

2025-04-160
PRE
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors

第十二届华氏巨球蛋白血症国际研讨会第五共识小组关于对共价BTK抑制剂不耐受或耐药患者管理的报告

2025-04-080
PREAI
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study (vol 109, pg 2297, 2024)

苯达莫司汀和利妥昔单抗作为症状性脾 marginal zone 淋巴瘤的一线治疗:长期结局及早期不可测量微小残留病获得的影响——来自 BRISMA/IELSG36 期 II 研究的数据(vol 109, pg 2297, 2024)

2025-04-010
OA
Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients

FIL MCL0208试验中,来那度胺维持治疗与观察在MCL患者自体干细胞移植(ASCT)后的长期结果

2025-03-220
OAAI
First-line treatment of Waldenstrom's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies
2024-11-190
OAAI
Determining the Mutational Landscape of Waldenstrom's Macroglobulinemia By Liquid Biopsy: Results of the Prospective Ecwm-2 Trial of the European Consortium for Waldenstrom's Macroglobulinemia

通过液体活检确定华氏巨球蛋白血症的突变景观:欧洲华氏巨球蛋白血症联盟前瞻性Ecwm-2试验的结果

BLOOD
IF23.1
2024-11-050
PRE